Tai joins Ensem Therapeutics with over 20 years of experience in small molecule drug discovery and development. Tai began his industry career at the Oncology Discovery Division of Bristol Myers Squibb, where he led several kinase inhibitors programs that advanced to early clinical development. At BMS, Tai also led a team in identifying and validating novel drug targets, and in the building of research capabilities including novel animal models and genomic annotation of cancer cell lines. Following his tenure at BMS, Tai took on the position of Vice President of Biology at Peloton Therapeutics. At Peloton, Tai and his team helped advance to clinical development the HIF-2a antagonist PT2977 (Belzutifan), that was recently approved by the FDA for treatment of renal cell cancer in patients with Von Hippel Lindau disease. His team performed transcription profiling studies that yielded data to inform patient selection and combination studies for further development in additional cancer indications. Before joining ENSEM, Tai was Vice President of Oncology Biology and Immunology at Skyhawk Therapeutics, where he led a team that developed small molecules for modulating RNA processing. 

Tai received his Ph.D. from the Rockefeller University and did post-doctoral training at Stanford University and Vanderbilt University. He is the co-author/co-inventor of over 60 peer-reviewed publications and issued patents.